151 related articles for article (PubMed ID: 9118037)
41. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.
Sloand EM; Barrett AJ
Hematol Oncol Clin North Am; 2010 Apr; 24(2):331-41. PubMed ID: 20359629
[TBL] [Abstract][Full Text] [Related]
42. [Combination of rabbit antithymocyte globulin plus cyclosporin A as first-line immunosuppressive therapy for the childhood with severe aplastic anemia.].
Liu LY; Wang HJ; Zhang L; Jing LP; Zhou K; Yang DL; Li HQ; Liu QG; Yan ZS; Liu YZ; Wu YH; Chu YL; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2009 Nov; 30(11):749-53. PubMed ID: 20137310
[TBL] [Abstract][Full Text] [Related]
43. Hypoplastic myelodysplastic syndrome transformed in acute myeloid leukemia after androgens and cyclosporin. A treatment.
Gologan R; Ostroveanu D; Dobrea C; Gioadă L
Rom J Intern Med; 2003; 41(4):447-55. PubMed ID: 15526527
[TBL] [Abstract][Full Text] [Related]
44. [Application of cyclosporine A in myelodysplastic syndrome--review].
Guan M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):678-80. PubMed ID: 14706160
[TBL] [Abstract][Full Text] [Related]
45. Outcome of children with aplastic anemia treated with immunosuppressive therapy.
Pongtanakul B; Das PK; Charpentier K; Dror Y
Pediatr Blood Cancer; 2008 Jan; 50(1):52-7. PubMed ID: 17941069
[TBL] [Abstract][Full Text] [Related]
46. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin.
Lim ZY; Killick S; Germing U; Cavenagh J; Culligan D; Bacigalupo A; Marsh J; Mufti GJ
Leukemia; 2007 Jul; 21(7):1436-41. PubMed ID: 17507999
[TBL] [Abstract][Full Text] [Related]
47. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.
Jonásova A; Neuwirtová R; Cermák J; Vozobulová V; Mociková K; Sisková M; Hochová I
Br J Haematol; 1998 Feb; 100(2):304-9. PubMed ID: 9488617
[TBL] [Abstract][Full Text] [Related]
48. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
Cantarovich D; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Lerat L; Moreau A; Soulillou JP
Nephrol Dial Transplant; 2000 Oct; 15(10):1673-6. PubMed ID: 11007839
[TBL] [Abstract][Full Text] [Related]
49. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
50. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study.
Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Ann Hematol; 2013 Jun; 92(6):817-24. PubMed ID: 23318980
[TBL] [Abstract][Full Text] [Related]
52. Myelodysplastic syndrome.
Nakao S; Deeg HJ; Ishikawa T; Marsh J; List A; Tomonaga M
Int J Hematol; 2005 Dec; 82(5):412-6. PubMed ID: 16533744
[No Abstract] [Full Text] [Related]
53. Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A.
Yamada T; Tsurumi H; Kasahara S; Hara T; Sawada M; Moriwaki H
J Cancer Res Clin Oncol; 2003 Aug; 129(8):485-91. PubMed ID: 12856174
[TBL] [Abstract][Full Text] [Related]
54. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
[TBL] [Abstract][Full Text] [Related]
55. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil.
Scheinberg P; Nunez O; Wu C; Young NS
Br J Haematol; 2006 Jun; 133(6):606-11. PubMed ID: 16704434
[TBL] [Abstract][Full Text] [Related]
56. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles.
Molldrem JJ; Jiang YZ; Stetler-Stevenson M; Mavroudis D; Hensel N; Barrett AJ
Br J Haematol; 1998 Sep; 102(5):1314-22. PubMed ID: 9753062
[TBL] [Abstract][Full Text] [Related]
57. Successful immunosuppressive therapy for a child with Myelodysplastic syndrome.
Orimoto M; Maeda M; Cai LZ; Hayakawa J; Ueda T; Migita M; Asano T
Med Pediatr Oncol; 2003 May; 40(5):334-5. PubMed ID: 12652627
[No Abstract] [Full Text] [Related]
58. [Cyclosporine A based therapy for myelodysplastic syndrome].
Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
[TBL] [Abstract][Full Text] [Related]
59. Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome.
Itoh M; Yago K; Shimada H; Tohyama K
Int J Hematol; 2002 Apr; 75(3):302-4. PubMed ID: 11999360
[TBL] [Abstract][Full Text] [Related]
60. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells.
Aivado M; Rong A; Stadler M; Germing U; Giagounidis A; Strupp C; Novotny J; Josten KM; Kobbe G; Hildebrandt B; Gattermann N; Aul C; Haas R; Ganser A
Eur J Haematol; 2002 Apr; 68(4):210-6. PubMed ID: 12071936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
